Key result
Recent advances in understanding the pathogenesis of post-thrombotic syndrome highlight residual venous obstruction as a central driver and identify flavonoids, statins, and leukocyte-endothelial interaction inhibitors as promising therapeutic targets.
Why the study?
Post-thrombotic syndrome is a frequent and detrimental complication of deep vein thrombosis with limited treatment options, and its prevention is currently hampered by the lack of unequivocally effective therapies.
Recent advances in understanding the pathogenesis of post-thrombotic syndrome highlight the central role of residual venous obstruction and point toward novel therapeutic targets such as flavonoids, statins, and leukocyte-endothelial interaction inhibitors.
No takes yet. Share an insight, caveat, or question.
May guide PTS risk stratification post-DVT; hypothesis-generating for FXI-targeted prevention trials.
Iding et al. (2022) conducted a review in Post-thrombotic syndrome (PTS) following deep vein thrombosis (DVT). Preventive therapies (e.g., elastic compressive therapy, anticoagulants, flavonoids, statins) was evaluated. Recent advances in understanding the pathogenesis of post-thrombotic syndrome highlight residual venous obstruction as a central driver and identify flavonoids, statins, and leukocyte-endothelial interaction inhibitors as promising therapeutic targets.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: